Myriad Genetics, Inc. reiterated earnings guidance for the fiscal year 2022. For the fiscal year 2022, the company now expects revenue in the range of $670 million - $700 million, and GAAP LPS of $0.90 - $0.70.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.74 USD | +1.81% | +0.31% | +18.97% |
May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
May. 31 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.97% | 2.02B | |
-5.37% | 12.35B | |
-3.75% | 8.17B | |
+7.79% | 5.77B | |
+32.02% | 5.65B | |
-12.12% | 4.1B | |
+14.18% | 2.67B | |
-5.70% | 2.31B | |
-6.70% | 1.81B | |
-3.89% | 1.51B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Myriad Genetics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022